Survival in patients with high-risk prostate cancer is predicted by mir-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2591-2603

  Kneitz, Burkhard ^a   Krebs, Markus ^a   Kalogirou, Charis ^a   Schubert, Maria ^a,c   Joniau, Steven ^f   Van Poppel, Hein ^f   Lerut, Evelyne ^f   Kneitz, Susanne ^b   Scholz, Claus Jürgen ^a   Ströbel, Philipp ^d   Gessler, Manfred ^b   Riedmiller, Hubertus ^a   Spahn, Martin ^a,e  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b IZKF Laboratory for Microarray Applications University Hospital Wuerzburg ^*  (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 2; JANUS KINASE; MICRORNA 221; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CELL GROWTH; CELL PROLIFERATION; DRUG SENSITIZATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-2; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTOME;

EID: 84900010677     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1606     Document Type: Article

References (49)

1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166 (Pubitemid 34031832)
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92 (Pubitemid 46359643)
3. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012;62:577-87
4. Sboner A,Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8
5. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005;173:1557-61 (Pubitemid 40528444)
6. Nguyen CT, Reuther AM, Stephenson AJ, Klein EA, Jones JS. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 2009;181:75-80
7. Yossepowitch O, Eggener SE, Bianco FJ Jr., Carver BS, Serio A, Scardino PT, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178:493-9; discussion 9
8. Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multiinstitutional study of 712 patients. Eur Urol 2010;58:1-7; discussion 10-1
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66 (Pubitemid 44629897)
10. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5 (Pubitemid 47037493)
11. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93 (Pubitemid 351380263)
12. Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008;12:1456-65
13. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010;127:394-403
14. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR- 221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 2012;10:119
15. Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, et al. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol 2012;227:3373-80
16. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012;18:74-82
17. Fu X, Wang Q, Chen J, Huang X, Chen X, Cao L, et al. Clinical significance of miR-221 and its inverse correlation with p27Kip(1) in hepatocellular carcinoma. Mol Biol Rep 2011;38:3029-35
18. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of c-Kit in cutaneous melanoma. Biochem Biophys Res Commun 2009;379: 790-4
19. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010;10:367
20. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16: 498-509
21. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-61
22. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res 2009;69:7375-84
23. Wang Y, Liu D, Chen P, Koeffler HP, Tong X, Xie D. Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 2008;68:1136-43 (Pubitemid 351272232)
24. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, et al. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 2007;96:296-305 (Pubitemid 46160635)
25. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70 (Pubitemid 40460553)
26. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62 (Pubitemid 41724921)
27. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L, et al. miR-221 is down-regulated in TMPRSS2:ERG fusionpositive prostate cancer. Anticancer Res 2011;31:403-10
28. Burock S, Meunier F, Lacombe D. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? Eur J Cancer 2013;49:2777-83
29. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, et al.PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63:4299-304 (Pubitemid 36950993)
30. Zollo M, Andre A, Cossu A, Sini MC, D'Angelo A, Marino N, et al. Overexpression of h-prune in breast cancer is correlated with advanced disease status. Clin Cancer Res 2005;11:199-205 (Pubitemid 40075796)
31. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN-g and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11 (Pubitemid 32391043)
32. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/ CIP1 mediated by STAT1. Science 1996;272:719-22
33. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, et al. Regulation of c-myc expression by IFN-g through Stat1-dependent and -independent pathways. EMBO J 2000;19: 263-72 (Pubitemid 30042708)
34. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303 (Pubitemid 29380565)
35. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005;58:833-8 (Pubitemid 41113390)
36. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96
37. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-8 (Pubitemid 26239777)
38. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000;42: 88-98 (Pubitemid 30056640)
39. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, et al. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006;169:2199-208 (Pubitemid 351181978)
40. Lu Y, Fukuyama S, Yoshida R, Kobayashi T, Saeki K, Shiraishi H, et al. Loss of SOCS3 gene expression converts STAT3 function from antiapoptotic to pro-apoptotic. J Biol Chem 2006;281:36683-90 (Pubitemid 46042135)
41. Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, et al. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer 2010;10:142
42. Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 2007;67:2535-43 (Pubitemid 46548938)
43. Yim JH, Ro SH, Lowney JK, WuSJ, Connett J, Doherty GM. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFNg growth inhibition of human breast carcinoma cell lines. J Interferon Cytokine Res 2003;23:501-11 (Pubitemid 37130073)
44. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58:729-39 (Pubitemid 19210966)
45. Hastie C. Interferon g, a possible therapeutic approach for late-stage prostate cancer? Anticancer Res 2008;28:2843-9
46. Bulbul MA, Huben RP, Murphy GP. Interferon-b treatment of metastatic prostate cancer. J Surg Oncol 1986;33:231-3
47. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, et al. miR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2013 Jun 19 [Epub ahead of print]
48. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, et al. The altered expression of miR-221/-222 and miR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 2012;72:1093-103
49. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 2007;14:1007-19. (Pubitemid 351252432)